Amicus Therapeutics is a biopharmaceutical company based in Cranbury, New Jersey. The company’s focus is on finding advanced therapies and treatments for a broad range of human genetic diseases. These diseases, known as orphan diseases, typically affect fewer than 200,000 people nationwide. Currently the company’s main concentration is on treatments for Lysosomal Storage Disorders such as Fabry disease and Pompe disease.
Amicus Therapeutics has directed their development on the Chaperone-Advanced Replacement Therapy (CHART) and enzyme replacement therapies (ERT). This kind of medical therapy replaces an enzyme that is either absent or deficient in the body. The patient is typically administered an IV which contains a solution of the
Amicus Therapeutics has directed their development on the Chaperone-Advanced Replacement Therapy (CHART) and enzyme replacement therapies (ERT). This kind of medical therapy replaces an enzyme that is either absent or deficient in the body. The patient is typically administered an IV which contains a solution of the